Department of Oncology, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde), Foshan, 528300, China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, And Collaborative Innovation, Center of Biotherapy, Chengdu, Sichuan, 610041, China.
Eur J Med Chem. 2020 Sep 15;202:112519. doi: 10.1016/j.ejmech.2020.112519. Epub 2020 Jun 27.
A series of Pyrazolo[1,5-a]Pyrimidine analogs were designed and synthesized as novel tubulin inhibitors. Among them, compounds 1a and 1b showed the highest antiproliferative activity against a panel of cancer cell lines with average IC values of 24.8 nM and 28 nM, respectively. We determined the crystal structures of 1a and 1b in complex with tubulin and confirmed their direct binding to the colchicine site. Compounds 1a and 1b also effectively inhibited tubulin polymerization in vitro, induced cell cycle arrest in G2/M phase, and inhibited cancer cell migration. In addition, compound 1b exhibited high metabolic stability in human liver microsomes. Finally, 1b was highly effective in suppressing tumor growth in a B16-F10 mouse melanoma model without apparent toxicity. In summary, these results suggest that 1b represents a promising tubulin inhibitor worthy of further investigation.
一系列吡唑并[1,5-a]嘧啶类似物被设计和合成,作为新型微管蛋白抑制剂。其中,化合物 1a 和 1b 对一组癌细胞系表现出最高的抗增殖活性,平均 IC 值分别为 24.8 nM 和 28 nM。我们确定了 1a 和 1b 与微管蛋白复合物的晶体结构,并证实了它们与秋水仙素结合部位的直接结合。化合物 1a 和 1b 还能有效抑制微管蛋白聚合,诱导细胞周期停滞在 G2/M 期,并抑制癌细胞迁移。此外,化合物 1b 在人肝微粒体中具有较高的代谢稳定性。最后,1b 在 B16-F10 小鼠黑色素瘤模型中能有效抑制肿瘤生长,且无明显毒性。总之,这些结果表明 1b 代表了一种有前途的微管蛋白抑制剂,值得进一步研究。